Barr Pharmaceuticals Inc

Barr Pharmaceuticals — Merger or Acquisition (July 2008)

29 slides from Barr Pharmaceuticals's merger presentation, Jul 21, 2008

  1. Slide 1: Teva and Barr: A strategic combination

    Teva and Barr A strategic combination July 2008

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This communication contains "forward-looking statements" which represent the current expectations and beliefs of management of Barr Pharmaceuticals, Inc. (the "Company") concerning the proposed merger of the Company with Boron Acquisition Corp., a wholly-owned subsidiary o

  3. Slide 3: Terms of Transaction

    Terms of Transaction 100% of Barr shares for total cash and stock consideration of $7.46 billion Plus, assumption of net debt of $1.5 billion Each Barr share converted to $39.90 in cash and 0.6272 Teva ADRs Per share consideration equivalent to $66.50

  4. Slide 4: What We Will Cover

    Why this transaction What does it mean for employees Overview of Teva From now through close What We Will Cover

  5. Slide 5: Why this transaction?

    Why this transaction?

  6. Slide 6: Teva Strategy

    Teva Strategy Increase market share in key markets Extend leadership in U.S. Establish leadership in key EU and International markets Double product portfolio Double R&D capabilities Focus on first-to-market / Paragraph IVs Double production capacity Biotechnology: Next growth wave in generics Inves

  7. Slide 7: Why Did Teva Choose Barr?

    Our vision and success in building a highly successful specialty pharmaceutical company Why Did Teva Choose Barr? Integrating the strengths of PLIVA and Barr Managing operations in more than 30 countries 8,900 people of Barr who have created a successful, competitive company Manufacturing and market

  8. Slide 8: Strategic Fit Between Barr and Teva

    Strategic Fit Between Barr and Teva Biologics Management Generics IP Legislative PIV Portfolio Teva brings: Broad Line Manufacturing Significant Global Scale Neuroscience, Specialty Pharma Tax Efficiency Barr brings: Niche Products Specialty Manufacturing Eastern & Central Europe Women's Healthcare

  9. Slide 9: A Proud and Defining Moment in Our History

    A Proud and Defining Moment in Our History Launch of generic version of Coumadin We were a pioneer in the U.S. generics industry Duramed Acquisition Acquisition of Paragard and approval of Dual label Plan-B Historic launch of tamoxifen citrate Acquisition of PLIVA Value of our barrier-to-entry strat

  10. Slide 10: Teva's Offer Positions Us for Even Greater Growth

    Teva's Offer Positions Us for Even Greater Growth Financial Strong business fundamentals in complementary geographies Exciting Global Growth Prospects both Product and Markets Generics Brands Biologics Minimal Overlap in Value and Volume Intangible World class capabilities to deliver affordable medi

  11. Slide 11: Key Combined Benefits

    Key Combined Benefits Annual revenues of approx. $11.9 billion 15.9% market share for all U.S. pharma companies 23.9% market share for all U.S. generic companies Operations in 60+ countries Generic industry leader in number and success rate of patent challenges 450+ marketed generic products in the

  12. Slide 12: What does this mean for Barr employees?

    What does this mean for Barr employees?

  13. Slide 13: Teva's growth strategy for 2008 - 2012

    Teva's growth strategy for 2008 - 2012 Double the business Reach revenues of $20 billion Exceed net income margins of 20% A Strategy Driven by Growth Opportunities for Barr Teva considers Barr employees a key asset of transaction Combination would create an even stronger global organization in a man

  14. Slide 14: Our Expectations

    Our Expectations Teva will seek to identify and cultivate talent from both organizations - we expect many opportunities for Barr/PLIVA employees to continue in combined company Teva will need to complete a detailed and objective review of the two businesses Barr's management team committed to workin

  15. Slide 15: Our Commitment

    Throughout the process, we are committed to being a responsible employer - people are our greatest asset! If any employees lose their jobs as a result of the transaction, they will be eligible for severance In Croatia employees are covered by Labor law, individual contracts, Employer's By-Laws and c

  16. Slide 16: Jobs, Pay and Benefits - Europe

    Jobs, Pay and Benefits - Europe Until close, no change - employees remain in their jobs with same pay and benefits as today At close, there is a change of control, e.g., ownership SARs - for employees who are eligible to have SARs Those granted prior to close will vest once Barr shareholders approve

  17. Slide 17: Example - Barr SARs

    Example - Barr SARs SARs cashed out at $66.50 less Exercise Price Let's say: You own 1,000 Barr SARs The Exercise Price for each SAR is $45 For each SAR, you will get $66.50 minus $45.00 = $21.50 (your gain) Therefore, for 1,000 SAR, you will get $21.50 X 1,000 = $21,500 gross For Croatia, taxes are

  18. Slide 18: Overview of Teva

    Overview of Teva

  19. Slide 19: Teva Operations

    Teva Operations Missouri Netherlands Hungary Italy India Israel Mexico Switzerland NJ Puerto Rico Czech Republic China Peru Chile Argentina Venezuela Toronto CA PA UK Brazil

  20. Slide 20: Core Strengths in Generics

    Core Strengths in Generics Broad product portfolio Largest first-to-file / Paragraph IV pipeline Technology: oral and semi solids, injectables, modified release, inhalants APIs/Vertical integration - approx. 250 compounds Intellectual property - over 1,000 patents Global supply chain

  21. Slide 21: Market Position in Europe

    Market Position in Europe Retail market position - selected markets UK Italy Netherlands Germany France Spain* Hungary Czech Poland Scandinavia* Belgium Market leader Not in top 10 In top 3 In top 10 Legend

  22. Slide 22: Strong Brand Business

    Strong Brand Business Copaxone(r): Largest product and its first major innovative drug, is a leading multiple sclerosis ("MS") therapy Azilect(r): Second significant innovative drug, indicated for the treatment of Parkinson's disease 5 projects in Phase III Clinical Studies Products in various devel

  23. Slide 23: Strong Commitment to Biologics

    Strong Commitment to Biologics G-CSF, interferon alpha 2b, and hGH (human growth hormone) sold in limited number of markets Manufacturing facilities in Mexico, Hungary and China Bulk substance manufacturing facilities in Lithuania and China CoGenesys' biotechnology research team, technologies and in

  24. Slide 24: From now through close

    From now through close

  25. Slide 25: Process to Close

    Process to Close Until close both companies operate separately and business as usual Successful close requires various approvals Hart-Scott-Rodino in the US Governments/Regulators in select European countries Barr Shareholders: November/December 2008 Close expected by end of 2008

  26. Slide 26: We Know You Have Questions

    We Know You Have Questions We have just announced the deal Many transition issues to work through Cannot yet answer many questions regarding: Synergy Targets Management team Facilities/operations

  27. Slide 27: We Commit to Communicate

    We Commit to Communicate Our promise - keep you informed throughout the entire process Meetings with Barr executives and facility and department meetings HR Updates, Company-wide memos, Global Intranet Managers: please hold meetings with your staff Refer all questions from Media and/or Shareholders

  28. Slide 28: Questions and Answers

    y? y Fo WY 4 | Questions and Answers Pharmaceutical, Ic

  29. Slide 29: Teva and Barr: A strategic combination

    Teva and Barr A strategic combination July 18, 2008

Barr Pharmaceuticals — Merger or Acquisition (July 2008) on 6ix